To understand what AATD is and what the consequences are for an individual with COPD
To identify target clientele who should be tested for AATD
To understand the diagnostic process
To understand the treatment, including augmentation therapy, as well as long-term adherence and lifestyle improvements to live better with AATD
Miriam Barrecheguren, MD, PhD is a pneumologist who currently works at Vall d’Hebron University Hospital in Barcelona. Her main areas of interest include COPD, AATD and mechanical ventilation. She has been a part of Alpha-1 Antitrypsin Deficiency Center at Vall d’Hebron University Hospital since 2013. After earning her Ph.D. in 2016, on the diagnosis and management of COPD and AATD in Primary Care, she fulfilled a research fellow at McGill University and was then granted a Rio Hortega grant to continue her work in Barcelona. She is the Early Career representative for the European Respiratory Society (ERS) in the European Alpha-1 research collaboration (EARCO).
Jean Bourbeau, MD, MSc, FRCPc, is the Director of the Research Institute MUHC’s Center for Innovative Medicine, the COPD Clinic and the Pulmonary Rehabilitation Unit at the MUHC Montreal Chest Institute. He has been President of the Canadian Thoracic Society. His work and research on COPD, pulmonary rehabilitation and integrated self-management programs for patients with COPD (Living Well With COPD) have had an impact not only in the field of research, but also in clinical practice at the national and international level.